Browse MCC

Summary
SymbolMCC
Namemutated in colorectal cancers
Aliases MCC1; Protein MCC; Colorectal mutant cancer protein
Chromosomal Location5q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane. Cell projection, lamellipodium. Nucleus Cytoplasm Note=Colocalizes with actin at the leading edge of polarized cells.
Domain PF10506 PDZ domain of MCC-2 bdg protein for Usher syndrome
Function

Candidate for the putative colorectal tumor suppressor gene located at 5q21. Suppresses cell proliferation and the Wnt/b-catenin pathway in colorectal cancer cells. Inhibits DNA binding of b-catenin/TCF/LEF transcription factors. Involved in cell migration independently of RAC1, CDC42 and p21-activated kinase (PAK) activation (PubMed:18591935, PubMed:19555689, PubMed:22480440). Represses the beta-catenin pathway (canonical Wnt signaling pathway) in a CCAR2-dependent manner by sequestering CCAR2 to the cytoplasm, thereby impairing its ability to inhibit SIRT1 which is involved in the deacetylation and negative regulation of beta-catenin (CTNB1) transcriptional activity (PubMed:24824780).

> Gene Ontology
 
Biological Process GO:0001667 ameboidal-type cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010633 negative regulation of epithelial cell migration
GO:0016055 Wnt signaling pathway
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030336 negative regulation of cell migration
GO:0040013 negative regulation of locomotion
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050680 negative regulation of epithelial cell proliferation
GO:0051271 negative regulation of cellular component movement
GO:0060070 canonical Wnt signaling pathway
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0198738 cell-cell signaling by wnt
GO:2000146 negative regulation of cell motility
Molecular Function -
Cellular Component GO:0030027 lamellipodium
GO:0031252 cell leading edge
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolMCC
Namemutated in colorectal cancers
Aliases MCC1; Protein MCC; Colorectal mutant cancer protein
Chromosomal Location5q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MCC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMCC
Namemutated in colorectal cancers
Aliases MCC1; Protein MCC; Colorectal mutant cancer protein
Chromosomal Location5q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MCC in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMCC
Namemutated in colorectal cancers
Aliases MCC1; Protein MCC; Colorectal mutant cancer protein
Chromosomal Location5q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MCC in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3060.412
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4930.71
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1680.87
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5370.0715
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.5980.798
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4680.865
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.320.48
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3160.849
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.9470.627
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3110.725
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0760.297
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5999.48e-05
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MCC in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.45.51.90.66
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.46.80.61
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610100-1000.143
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMCC
Namemutated in colorectal cancers
Aliases MCC1; Protein MCC; Colorectal mutant cancer protein
Chromosomal Location5q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MCC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMCC
Namemutated in colorectal cancers
Aliases MCC1; Protein MCC; Colorectal mutant cancer protein
Chromosomal Location5q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MCC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MCC.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMCC
Namemutated in colorectal cancers
Aliases MCC1; Protein MCC; Colorectal mutant cancer protein
Chromosomal Location5q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MCC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMCC
Namemutated in colorectal cancers
Aliases MCC1; Protein MCC; Colorectal mutant cancer protein
Chromosomal Location5q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MCC expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMCC
Namemutated in colorectal cancers
Aliases MCC1; Protein MCC; Colorectal mutant cancer protein
Chromosomal Location5q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MCC and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMCC
Namemutated in colorectal cancers
Aliases MCC1; Protein MCC; Colorectal mutant cancer protein
Chromosomal Location5q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MCC collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.